Fibromyalgia Coenzyme Q10 Brain activity Mitochondrial function Fibromyalgia
Conditions
Interventions
Placebo will be given for 40 days,Coenzyme Q10 will be given for 40 dyas (300 mg/day divided into 3 doses)
Placebo Comparator Drug,Experimental Drug
Placebo,CoQ10
Sponsors
Faculty of Medicine, Chiang Mai University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: - Patients who were diagnosed of fibromyalgia, based on current American College of Rheumatology (ACR) criteria for fibromyalgia 2010 (Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5 or WPI 3-6 and SS scale score ≥ 9, Symptoms have been present at a similar level for at least 3 months and patient does not have a disorder that would otherwise explain the pain)
Exclusion criteria
Exclusion criteria: - Allergic to pregabalin and coenzyme Q10 - Severe physical impairment, coexisting physical injury - Comorbid medical illnesses (morbid obesity, autoimmune diseases, cardiopulmonary diseases, uncontrolled endocrine disorders, uncontrolled allergic disorder/ asthma, cancer, and/or medical history of significant head injury or neurological disorder) - Existing psychopathological disorder (history of psychosis, current suicide riskor attemptwithin 2 years of the study - History of substance abuse,major depressive disorder) - Pregnancy - Use of recreationaldrugs - Alcohol consumption of more than 40 g per dayand pregnancy or current breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Brain activity in associated with pain sensation from fibromyalgia patients At D0, D40 and D80 of study PET CT Scan,mitochondrial function and oxidative stress level and inflammatory level from BMCs cells At D0, D40 and D80 of study Blood test | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Public ContactPassakorn Sawaddiruk
Faculty of Medicine, Chiang Mai University
Outcome results
None listed